Checkpoint immunotherapy: Good for cancer therapy, bad for rheumatic diseases

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 1-3

  Calabrese, Leonard ^a   Velcheti, Vamsidhar ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; ANTIRHEUMATIC AGENT;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADRENAL INSUFFICIENCY; ANTIGEN PRESENTING CELL; AUTOIMMUNE HYPOPHYSITIS; CANCER THERAPY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COLITIS; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DISEASE COURSE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MACULOPAPULAR RASH; MAJOR HISTOCOMPATIBILITY COMPLEX; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATIC DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; THYROID DISEASE; TOXIC EPIDERMAL NECROLYSIS; NEOPLASM;

ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RHEUMATIC DISEASES;

EID: 84984663113     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209782     Document Type: Review

References (18)

1. Brouckaert PG, Fiers W, Lejeune FJ. Coley's vaccine and TNF therapy. Nature 1992; 358: 630.
2. Velcheti V, Schalper K. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book 2016; 35: 298-308.
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61.
4. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37.
5. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1: 32-42.
6. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13: 473-86.
7. Marrone KA, Ying W, Naidoo J. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther 2016; 100: 242-51.
8. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210-25.
9. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-8.
10. Zumwalt TJ, Goel A. Immunotherapy of metastatic colorectal cancer: prevailing challenges and new perspectives. Curr Colorectal Cancer Rep 2015; 11: 125-40.
11. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-51.
12. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
13. Topalian SL, Sharpe AH. Balance and imbalance in the immune system: life on the edge. Immunity 2014; 41: 682-4.
14. McKinney EF, Lee JC, Jayne DR, et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 2015; 523: 612-16.
15. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017; 76: 43-50.
16. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2: 234-40.
17. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 1270-1.
18. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol 2015; 6: 418.